Exos Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Exos Asset Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$54K	Hold	572	–	–	0.03%	211
2022 Q1	$92K	Buy	572 +232	+68%	+$45.2K	0.04%	207
2021 Q4	$113K	Sell	340 -153	-31%	-$72.7K	0.06%	233
2021 Q3	$229K	Buy	+493	New	+$240K	0.12%	228

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Exos Asset Management's DNA Position: Q2 2022 in Review

Exos Asset Management held its Ginkgo Bioworks (DNA) position steady in Q2 2022 at 572 shares worth $54K. The position accounts for 0.03% of the portfolio, ranked #211.

Exos Asset Management first reported a position in DNA in Q3 2021 and has held it in 4 quarters since. The position peaked at $229K in Q3 2021. 260 funds tracked by Wall St. Rank hold DNA as of Q2 2022.

Exos Asset Management held 572 shares of Ginkgo Bioworks worth $54K as of Q2 2022.
Exos Asset Management left its Ginkgo Bioworks share count unchanged in Q2 2022.
Ginkgo Bioworks made up 0.03% of Exos Asset Management's portfolio in Q2 2022, its #211 holding.
Exos Asset Management first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 4 quarters since.
Exos Asset Management's Ginkgo Bioworks position peaked at $229K in Q3 2021.
260 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2022.

Based on Exos Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.